Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
4.8
out of 5.0
A long-acting GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management, achieving ~15-17% body weight reduction in clinical trials.
Research Overview
Semaglutide activates the GLP-1 receptor, which is expressed in the pancreas, brain, heart, and gastrointestinal tract. In the pancreas, it enhances glucose-dependent insulin secretion and suppresses glucagon release. In the brain, it acts on hypothalamic appetite centers to reduce hunger and food intake. These combined effects produce significant improvements in glycemic control and sustained weight loss.
FDA-approved as Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral, type 2 diabetes), semaglutide has demonstrated remarkable efficacy across multiple large-scale clinical trials. The STEP trials showed mean weight loss of 14.9-17.4% over 68 weeks. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes. Semaglutide has become one of the most commercially successful and culturally impactful pharmaceutical products in modern history.
Documented Research Effects
Dosage & Protocol
Typical Dose Range
250 – 2400
mcg per dose
Frequency
1x weekly
Cycle Length
Ongoing (chronic therapy)
Common Vial Sizes
Calculate exact draw volumes and reconstitution steps.
Use CalculatorDosage information is for research reference only. Always follow established research protocols. Not medical advice.
Storage & Handling
Lyophilized Powder
Reconstituted Solution
Frequently Asked Questions
Semaglutide activates GLP-1 receptors in the brain's hypothalamus, reducing appetite and food cravings while slowing gastric emptying to increase feelings of fullness. It also improves insulin sensitivity and glucose metabolism. The combination of reduced caloric intake and improved metabolic function produces sustained weight loss averaging 15-17% of body weight over 68 weeks in clinical trials.
Semaglutide is titrated gradually to reduce gastrointestinal side effects. The standard protocol starts at 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, reaching the target dose of 2.4 mg weekly (for Wegovy/weight management). Each dose level is maintained for at least 4 weeks before escalation. Do not skip titration steps.
The most common side effects are gastrointestinal: nausea (affecting ~44% of users), diarrhea, vomiting, constipation, and abdominal pain. These are most pronounced during dose titration and typically diminish over 4-8 weeks. Eating smaller meals, avoiding fatty/greasy foods, and staying hydrated can help manage symptoms. More serious but rare side effects include pancreatitis, gallbladder disease, and thyroid C-cell tumors (observed in rodent studies).
Yes, semaglutide is available in oral form as Rybelsus, which is FDA-approved for type 2 diabetes (not weight management). It uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) to enable stomach absorption. Oral semaglutide must be taken on an empty stomach with no more than 4 oz of water, waiting at least 30 minutes before eating or drinking. The oral bioavailability is approximately 1%, requiring higher doses (3, 7, or 14 mg daily) compared to the injectable form.
Research shows that approximately two-thirds of weight lost during semaglutide treatment is regained within one year of discontinuation. Appetite returns to baseline levels, and the metabolic benefits (improved insulin sensitivity, reduced inflammation) diminish. For this reason, semaglutide is generally considered a long-term or chronic therapy rather than a short-term intervention. Some practitioners recommend gradual dose tapering rather than abrupt discontinuation.
Community Reviews
All 245 reviews →No Reviews Yet
Community reviews for Semaglutide are being collected. Check back soon.